Company intelligence / Profile preview

R3 Stem Cell

Phoenix, Arizona, United Statesr3stemcell.com ↗

Ownership: Private
Development stage: Commercial

Overview

R3 Stem Cell has performed over 25,000 regenerative procedures globally with an 85% reported patient satisfaction rate. The company claims to offer safe and effective therapies using cGMP/ISO-certified biologics. It has Institutional Review Board approval for research studies in several indications and plans to commence Phase I clinical trials for opiate addiction, erectile dysfunction, knee arthritis and autism. No published peer-reviewed clinical trial results are available as of June 2025.

Therapeutic areas: Men's HealthPulmonologyImmunologyPsychiatryRheumatologyNeurologyCardiovascularNephrology
Modalities: Stem cell therapyExosome-based therapyPlatelet-rich plasma therapyPeptidesBiologic
Industry: Biotech

Drug pipeline

1 asset

Wharton's jelly allograft (R3 Stem Cell)

Unknown

Partnerships

None publicly disclosed with major pharmaceutical or biotech companies.

Beyond the preview

Go deeper on R3 Stem Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R3 Stem Cell.

Explore the full profile